Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Teva Pharmaceutical Industries Limited Ordinary Shares
(NY:
TEVA
)
41.79
+2.54 (+6.47%)
Delayed Quote
Updated: 12:33 PM EDT, Oct 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Teva Pharmaceutical Industries Limited Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
35
36
Next >
Teva Wins FDA Approval for Monthly Schizophrenia Injectable WELTRUZA
↗
Today 12:02 EDT
Teva Pharmaceutical Industries (NYSE:TEVA) said the U.S. Food and Drug Administration has approved WELTRUZA, a once-monthly subcutaneous long-acting injectable formulation of olanzapine for...
Via
MarketBeat
Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia
Today 7:00 EDT
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome
October 02, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients
October 02, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Pharmaceutical (NYSE:TEVA) Nears Breakout With Perfect Technical Rating and Bull Flag Setup
↗
October 01, 2026
Via
Chartmill
TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness
September 30, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround
↗
September 29, 2026
Built on substance, not hype, Teva's mega rally is just getting started.
Via
The Motley Fool
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
September 28, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Releases Q3 2026 Aide Memoire
September 23, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
September 23, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Eyes New Growth Phase After Securing Investment-Grade Ratings
↗
September 23, 2026
Teva Pharmaceutical Industries (NYSE:TEVA) is planning for greater financial flexibility after receiving investment-grade ratings from all three major credit rating agencies, President and CEO Richard...
Via
MarketBeat
Topics
Bankruptcy
Teva CEO Details Biopharma Pivot, $700M Savings Plan and Growth Pipeline
↗
September 22, 2026
Teva Pharmaceutical Industries (NYSE:TEVA) Chief Executive Officer Richard Francis said the company has shifted from being viewed primarily as a generics manufacturer toward a biopharmaceutical company...
Via
MarketBeat
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
September 18, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
September 18, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
September 18, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care
September 16, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Says Pivot to Growth Gains Steam as Branded Drugs, Biosimilars Outperform
↗
September 14, 2026
Teva Pharmaceutical Industries (NYSE:TEVA) CEO Richard Francis said the company has progressed from the initial phase of its “Pivot to Growth” plan into its next stage, citing momentum in branded...
Via
MarketBeat
Topics
World Trade
Teva Pharmaceuticals Sees Pivot to Growth Accelerating on Branded Drugs, Biosimilars
↗
September 14, 2026
Teva Pharmaceutical Industries (NYSE:TEVA) said its “Pivot to Growth” strategy has moved into its second phase, with management pointing to momentum in branded medicines, a stabilized generics...
Via
MarketBeat
Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy
September 14, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes
September 10, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Announces Launch of Offering of Senior Notes
September 07, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline
September 04, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva’s TEV-408 Hits Key Phase IIa Endpoint in Celiac Disease Study
↗
September 02, 2026
Teva Pharmaceutical Industries (NYSE:TEVA) reported positive topline results from a Phase IIa gluten-challenge study of TEV-408, its anti-IL-15 antibody candidate for celiac disease, with the company...
Via
MarketBeat
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential
September 02, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September
September 01, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.
August 31, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
August 28, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
August 19, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy
August 11, 2026
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva (TEVA) Q2 2026 Earnings Call Transcript
↗
August 07, 2026
Key innovative brands now generate over $1B quarterly revenue.
Via
The Motley Fool
Topics
Earnings
< Previous
1
2
3
4
5
6
7
8
9
...
35
36
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
